The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Our cells need to be able to recognize potential invaders as a threat, the key function of the body's innate immune system.

In this process, RNA transmits genetic information that ribosomes translate into different proteins essential for cellular ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Mammalian RNAs can be edited by the conversion of adenosine to inosine, which is read as guanosine, but technological constraints have limited our view of the overall contribution of RNA editing ...

The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible.

By studying this amazing structure, how did scientists learn about RNA editing? The first tools developed for the study of cells and tissues were optical microscopes. These microscopes use visible ...

The gene editing technology CRISPR has revolutionized ... However, a newer technology uses the enzyme Cas13 to more precisely target RNA without disrupting nearby protein-coding genes and other ...

"This open IND for HG202 by the U.S. FDA-the first regulator to clear CRISPR/Cas13 for clinical development–marks a significant milestone for HuidaGene and the CRISPR RNA-editing field," noted ...

The firm highlighted the biotech company's focus on RNA editing as a significant factor in its positive outlook. Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD ...

Wave also introduced new, wholly owned GalNAc-RNA editing programs and demonstrated its leadership in oligonucleotide chemistry innovation. “This year, we showed through multiple positive clinical ...